Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krebs Biochemicals reported a significant revenue decline to Rs 2,373.16 Lacs in FY26 from Rs 4,331.19 Lacs in FY25—a drop of approximately 45%. The company continues to incur losses with a net loss of Rs 1,693.31 Lacs, though this is an improvement from the previous year's loss of Rs 2,692.40 Lacs. The net worth is deeply negative at Rs (16,275.47) Lacs due to accumulated losses. Operations at the Vizag manufacturing unit remain suspended since February 2025 following an Andhra Pradesh Pollution Control Board order. The statutory auditor issued an unmodified (clean) opinion on the financial statements. The company also has negative cash flow from operating activities of Rs (192.05) Lacs and outstanding redeemable preference shares worth Rs 13,000 Lacs.
The company is in severe financial distress with negative equity and ongoing losses. Despite a reduction in losses year-over-year, the deeply negative net worth and suspended operations raise significant concerns about the company's ability to continue as a going concern without external support or restructuring.